One segment, three revenue lines, and product sales carry 72%
The business view is one segment: the Reportable Segment accounts for 100% of the $353.17 M of revenue. Inside it, net product revenue is $253.35 M, license and services revenue $79.31 M, and royalty revenue $20.51 M. Product sales carry 72% of the total, and the rest is a mix of milestones and royalties from partners. The company says it runs one business, so this view splits one business into three lines, not three businesses. That is the filing's own framing, not ours.
The quarter's growth came from the smaller lines. License and services revenue rose from $8.31 M to $79.31 M, or 9.5 times its level a year earlier, while net product revenue grew 134%. The filing ties that license jump to the $75.0 M milestone, so product sales are the steady part and license revenue is the lumpy part. Nine months tell the same story, with license revenue down 29% from a year earlier while product sales climbed.
What it means: one name, three businesses. Royalty revenue rose from $4.28 M to $20.51 M on Beyonttra sales in the EU and Japan, and the filing expects more from partners such as Bayer and Alexion. Products that sell, licenses that pay out once, and royalties that depend on partners' sales do not behave alike. Mixing them into one segment hides which line is carrying the company. Will royalty revenue keep rising as partners sell more, or will milestones keep the top line lumpy?

